Pharmacokinetics, biodistribution, and toxicity evaluation of Anti-SEMA3A (F11) in in vivo models

Jaehyun Lee, Donggeon Kim, Eunju Son, Su Ji Yoo, Jason K. Sa, Yong Jae Shin, Yeup Yoon, Do Hyun Nam

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Background/Aim: The aim of our study was to investigate the pharmacokinetics (PK), tissue distribution and toxicity of F11 antibody to semaphorin 3A in mouse models and explore its anti-angiogenic and tumor-inhibitory effect. Materials and Methods: Patient-derived xenograft (PDX) models were established via subcutaneous implantation of glioblastoma multiforme (GBM) cells and treated with F11. Results: F11 significantly attenuated tumor growth and angiogenesis in the GBM PDX model. Within the range of administered doses, the PK of F11 in serum demonstrated a linear fashion, consistent with general PK profiles of soluble antigen-targeting antibodies. Additionally, the clearance level was detected at between 4.63 and 7.12 ml/d/kg, while the biological half-life was measured at 6.9 and 9.4 days. Tissue distribution of F11 in kidney, liver and heart was consistent with previously reported antibody patterns. However, the presence of F11 in the brain was an interesting finding. Conclusion: Collectively, our results revealed angiogenic and tumor-inhibitory effect of F11 antibody and its potential therapeutic use within a clinical framework based on PK, biodistribution and toxicity evaluation in mouse models.

Original languageEnglish
Pages (from-to)2803-2810
Number of pages8
JournalAnticancer research
Issue number5
Publication statusPublished - 2018 May
Externally publishedYes


  • Fully human antibody
  • Pharmacokinetics
  • SEMA3A
  • Semaphorin3A
  • Tissue distribution
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Pharmacokinetics, biodistribution, and toxicity evaluation of Anti-SEMA3A (F11) in in vivo models'. Together they form a unique fingerprint.

Cite this